Tonix Pharmaceuticals Holding Corp (TNXP) with a beta value of 2.10 appears to be a promising investment opportunity.

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) on Monday, plunged -4.32% from the previous trading day, before settling in for the closing price of $39.78. Within the past 52 weeks, TNXP’s price has moved between $6.76 and $550.40.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The company achieved an average annual earnings per share of 92.54%. With a float of $7.32 million, this company’s outstanding shares have now reached $7.32 million.

The firm has a total of 81 workers. Let’s measure their productivity. In terms of profitability, gross margin is 29.81%, operating margin of -721.51%, and the pretax margin is -1146.27%.

Tonix Pharmaceuticals Holding Corp (TNXP) Breakdown of a Key Holders of the stock

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Tonix Pharmaceuticals Holding Corp is 0.07%, while institutional ownership is 6.61%. The most recent insider transaction that took place on May 15 ’25, was worth 86,200. In this transaction Chief Executive Officer of this company bought 4,000 shares at a rate of $21.55, taking the stock ownership to the 4,005 shares.

Tonix Pharmaceuticals Holding Corp (TNXP) Recent Fiscal highlights

According to the Wall Street analysts, stocks earnings will be around 92.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 88.07% during the next five years compared to 46.06% growth over the previous five years of trading.

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) Trading Performance Indicators

Tonix Pharmaceuticals Holding Corp (TNXP) is currently performing well based on its current performance indicators. A quick ratio of 11.64 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 27.77.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -32.12, a number that is poised to hit -6.83 in the next quarter and is forecasted to reach -6.08 in one year’s time.

Technical Analysis of Tonix Pharmaceuticals Holding Corp (TNXP)

Analysing the last 5-days average volume posted by the [Tonix Pharmaceuticals Holding Corp, TNXP], we can find that recorded value of 1.65 million was better than the volume posted last year of 1.41 million. As of the previous 9 days, the stock’s Stochastic %D was 84.22%. Additionally, its Average True Range was 3.74.

During the past 100 days, Tonix Pharmaceuticals Holding Corp’s (TNXP) raw stochastic average was set at 60.73%, which indicates a significant decrease from 79.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 147.54% in the past 14 days, which was lower than the 217.25% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $22.28, while its 200-day Moving Average is $21.31. Now, the first resistance to watch is $40.06. This is followed by the second major resistance level at $42.05. The third major resistance level sits at $43.70. If the price goes on to break the first support level at $36.42, it is likely to go to the next support level at $34.77. Now, if the price goes above the second support level, the third support stands at $32.78.

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) Key Stats

Market capitalization of the company is 278.78 million based on 7,325K outstanding shares. Right now, sales total 10,090 K and income totals -130,040 K. The company made 2,430 K in profit during its latest quarter, and -16,830 K in sales during its previous quarter.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.